Sirona Biochem Corp
Sirona Biochem Corp., a cosmetic ingredient and drug discovery company, engages in the development and sale of cosmetic and pharmaceutical active ingredients in Canada and France. The company's programs include cosmetic skin lightener and diabetes drug; and other projects comprise the development of an anti-aging/cell protection library, anti-wrinkle compound, and anti-viral program. The company … Read more
Sirona Biochem Corp (SRBCF) - Total Liabilities
Latest total liabilities as of July 2024: $4.27 Million USD
Based on the latest financial reports, Sirona Biochem Corp (SRBCF) has total liabilities worth $4.27 Million USD as of July 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Sirona Biochem Corp - Total Liabilities Trend (2007–2023)
This chart illustrates how Sirona Biochem Corp's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Sirona Biochem Corp Competitors by Total Liabilities
The table below lists competitors of Sirona Biochem Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
TechCom Inc
PINK:TCRI
|
USA | $292.08K |
|
Tokyo Plast International Limited
NSE:TOKYOPLAST
|
India | ₹648.59 Million |
|
Tower One Wireless Corp
STU:1P3N
|
Germany | €50.43 Million |
|
Inca Minerals Ltd
AU:ICG
|
Australia | AU$283.19K |
|
Shuttle Pharmaceuticals Inc
NASDAQ:SHPH
|
USA | $2.15 Million |
|
Kula Gold Ltd
AU:KGD
|
Australia | AU$620.24K |
|
Damodar Industries Limited
NSE:DAMODARIND
|
India | ₹2.04 Billion |
|
Diagnamed Holdings Corp.
PINK:DGNMF
|
USA | $666.47K |
Liability Composition Analysis (2007–2023)
This chart breaks down Sirona Biochem Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.34 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.23 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 5.28 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sirona Biochem Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sirona Biochem Corp (2007–2023)
The table below shows the annual total liabilities of Sirona Biochem Corp from 2007 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-10-31 | $3.54 Million | +229.26% |
| 2022-10-31 | $1.08 Million | -22.27% |
| 2021-10-31 | $1.38 Million | -33.75% |
| 2020-10-31 | $2.09 Million | +1.09% |
| 2019-10-31 | $2.07 Million | -31.80% |
| 2018-10-31 | $3.03 Million | -7.90% |
| 2017-10-31 | $3.29 Million | +110.75% |
| 2016-10-31 | $1.56 Million | -34.87% |
| 2015-10-31 | $2.40 Million | +46.43% |
| 2014-10-31 | $1.64 Million | +31.22% |
| 2013-10-31 | $1.25 Million | +27.82% |
| 2012-10-31 | $976.43K | +34.26% |
| 2011-10-31 | $727.26K | +160.52% |
| 2010-10-31 | $279.16K | +444.29% |
| 2009-10-31 | $51.29K | +6.19% |
| 2008-10-31 | $48.30K | -0.87% |
| 2007-10-31 | $48.72K | -- |